A recent case of severe, but reversible, hypoplastic anemia was associated temporally with lindane exposure. A series of 46 cases of hematotoxicity associated with lindane is reviewed, and the weaknesses in the indictment of lindane as the causative agent are pointed out. A more rational policy for control of agents suspected of damaging bone marrow awaits improved understanding of pathogenetic mechanisms.